1
|
Pascal M, Edelman SM, Nopp A, Möbs C, Geilenkeuser WJ, Knol EF, Ebo DG, Mertens C, Shamji MH, Santos AF, Patil S, Eberlein B, Mayorga C, Hoffmann HJ. EAACI task force report: A consensus protocol for the basophil activation test for collaboration and external quality assurance. Allergy 2024; 79:290-293. [PMID: 37795777 PMCID: PMC10843141 DOI: 10.1111/all.15907] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2023] [Revised: 09/18/2023] [Accepted: 09/25/2023] [Indexed: 10/06/2023]
Affiliation(s)
- M Pascal
- Immunology Department, Centre de Diagnòstic Biomèdic, Hospital Clínic de Barcelona, Barcelona, Spain
- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain
- RETICS Asma reacciones adversas y alérgicas (ARADYAL) and RICORS Red De Enfermedades Inflamatorias (REI), Madrid, Spain
| | - S M Edelman
- Skin and Allergy Hospital, Helsinki University Central Hospital, Helsinki, Finland
| | - A Nopp
- Department of Clinical Science and Education, Karolinska Institutet, Södersjukhuset, and Sachs´ Children and Youth Hospital, Stockholm, Sweden
| | - C Möbs
- Department of Dermatology and Allergology, Philipps-Universität Marburg, Marburg, Germany
| | | | - E F Knol
- Center of Translational Immunology and Dermatology/Allergology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - D G Ebo
- Faculty of Medicine and Health Sciences, Department of Immunology-Allergology- Rheumatology, University of Antwerp, Antwerp, Belgium
| | - C Mertens
- Faculty of Medicine and Health Sciences, Department of Immunology-Allergology- Rheumatology, University of Antwerp, Antwerp, Belgium
| | - M H Shamji
- National Heart and Lung Institute, Imperial College London, London, UK
- NIHR Imperial Biomedical Research Centre, London, UK
| | - A F Santos
- Department of Women and Children's Health (Pediatric Allergy) & Peter Gorer Department of Immunobiology, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom
- Children's Allergy Service, Evelina London Children's Hospital, Guy's and St Thomas' Hospital, London, United Kingdom
| | - S Patil
- Division of Allergy and Immunology, Departments of Medicine and Pediatrics, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States
| | - B Eberlein
- Department of Dermatology and Allergy Biederstein, School of Medicine, Technical University Munich, Munich, Germany
| | - C Mayorga
- RETICS Asma reacciones adversas y alérgicas (ARADYAL) and RICORS Red De Enfermedades Inflamatorias (REI), Madrid, Spain
- Allergy Clinical Unit, Hospital Regional Universitario de Málaga and Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA-BIONAND, Málaga, Spain
| | - H J Hoffmann
- Department of Clinical Medicine, Aarhus University, Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark
| |
Collapse
|
2
|
Polakova A, Didona D, Holstein J, Baum C, Solimani F, Ghoreschi K, Hertl M, Pfützner W, Möbs C. 034 Impaired frequency and function of transitional B cells in patients with pemphigus vulgaris. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.09.043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
3
|
Hennighausen I, Pickert J, Mühlenbein S, Möbs C, Pfützner W. Successful Covid-19 vaccination of a patient with hypersensitivity against polyethylene glycol and polysorbate. J Investig Allergol Clin Immunol 2022; 32:322-323. [DOI: 10.18176/jiaci.0801] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
4
|
Polakova A, Kauter L, Ismagambetova A, Möbs C, Hudemann C. 026 Detection of rare autoreactive T cell subsets in patients with pemphigus vulgaris by the CD154 activation assay. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.08.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
5
|
Pickert J, Hennighausen I, Mühlenbein S, Möbs C, Pfützner W. Immediate-Type Hypersensitivity to Polyethylene Glycol (PEG) Including a PEG-containing COVID-19 Vaccine Revealed by Intradermal Testing. J Investig Allergol Clin Immunol 2021; 31:526-527. [PMID: 34132638 DOI: 10.18176/jiaci.0720] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- J Pickert
- Clinical&Experimental Allergology, Department of Dermatology and Allergology, Philipps-Universität Marburg, Marburg, Germany.,Department of Dermatology and Allergology, Allergy Center Hessen, University Medical Center Marburg, Marburg, Germany
| | - I Hennighausen
- Department of Dermatology and Allergology, Allergy Center Hessen, University Medical Center Marburg, Marburg, Germany
| | - S Mühlenbein
- Department of Dermatology and Allergology, Allergy Center Hessen, University Medical Center Marburg, Marburg, Germany
| | - C Möbs
- Clinical&Experimental Allergology, Department of Dermatology and Allergology, Philipps-Universität Marburg, Marburg, Germany
| | - W Pfützner
- Clinical&Experimental Allergology, Department of Dermatology and Allergology, Philipps-Universität Marburg, Marburg, Germany.,Department of Dermatology and Allergology, Allergy Center Hessen, University Medical Center Marburg, Marburg, Germany
| |
Collapse
|
6
|
Rauber M, Pickert J, Holiangu L, Möbs C, Pfützner W. Omalizumab response correlates with reduced
IFN
‐γ‐,
IL
‐10‐ and
IL
‐31‐secreting cells in chronic spontaneous urticaria. J Eur Acad Dermatol Venereol 2020; 34:2078-2085. [DOI: 10.1111/jdv.16216] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2019] [Accepted: 11/19/2019] [Indexed: 12/31/2022]
Affiliation(s)
- M.M. Rauber
- Clinical & Experimental Allergology Department of Dermatology and Allergology Philipps‐Universität Marburg Marburg Germany
- Experimental Dermatology and Allergy Research Group Justus‐Liebig‐University Giessen Giessen Germany
| | - J. Pickert
- Department of Dermatology and Allergology Allergy Centre Hessen University Medical Centre Marburg Marburg Germany
| | - L. Holiangu
- Department of Dermatology and Allergology Allergy Centre Hessen University Medical Centre Marburg Marburg Germany
| | - C. Möbs
- Clinical & Experimental Allergology Department of Dermatology and Allergology Philipps‐Universität Marburg Marburg Germany
| | - W. Pfützner
- Clinical & Experimental Allergology Department of Dermatology and Allergology Philipps‐Universität Marburg Marburg Germany
- Department of Dermatology and Allergology Allergy Centre Hessen University Medical Centre Marburg Marburg Germany
| |
Collapse
|
7
|
Solimani F, Baum C, Holstein J, Pollmann R, Didona D, Eming R, Hertl M, Pfutzner W, Ghoreschi K, Möbs C. 080 Modulation of the T helper and T follicular helper cell distribution in pemphigus patients by B cell-depleting therapy. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.07.083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
8
|
Abstract
BACKGROUND Personalized medicine offers new perspectives for diagnostic measurements and medical treatment, but also puts greater demands on the physician. OBJECTIVES Developments, potentials and potential pitfalls of personalized medicine in allergology. METHODS Overview, evaluation and discussion of the current state of science on the basis of selected examples. RESULTS Allergic diseases like allergic rhinitis, atopic eczema or anaphylaxis can be classified into various clinical phenotypes, which are based on different immunological endotypes. These can be captured and categorized by a wide variety of omics technologies. The identification of endotype specific biomarkers holds promising opportunities of more precise diagnostics, the implementation of novel targeted therapies or the development of optimized preventive strategies. However, individualized analysis and assessment of the significance of the measurements represent special challenges. CONCLUSIONS Findings of the complex omics technologies need to be evaluated by comprehensive prospective studies in order to validate their clinical relevance and suitability for personalized medicine in allergology.
Collapse
Affiliation(s)
- W Pfützner
- Klinik für Dermatologie und Allergologie, Allergie Zentrum Hessen, Universitätsklinikum Gießen und Marburg, Standort Marburg, Philipps-Universität Marburg, Baldinger Str., 35043, Marburg, Deutschland.
| | - J Pickert
- Klinik für Dermatologie und Allergologie, Allergie Zentrum Hessen, Universitätsklinikum Gießen und Marburg, Standort Marburg, Philipps-Universität Marburg, Baldinger Str., 35043, Marburg, Deutschland
| | - C Möbs
- Klinik für Dermatologie und Allergologie, Allergie Zentrum Hessen, Universitätsklinikum Gießen und Marburg, Standort Marburg, Philipps-Universität Marburg, Baldinger Str., 35043, Marburg, Deutschland
| |
Collapse
|
9
|
Kiselmann C, Dobler D, Schmidts T, Eicher AC, Möbs C, Pfützner W, Runkel F. Development of a skin-friendly microemulsion for dermal allergen-specific immunotherapy. Int J Pharm 2018; 550:463-469. [PMID: 30194011 DOI: 10.1016/j.ijpharm.2018.09.002] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2018] [Revised: 08/30/2018] [Accepted: 09/04/2018] [Indexed: 01/29/2023]
Abstract
Due to their role in immune responses, the skin dendritic cells (i.e. epidermal Langerhans cells and dermal dendritic cells) have become of great interest to researchers in the past decades. A dermal administration of allergens could target these professional antigen-presenting cells directly and build up immunotolerance. Additionally, many of the adverse side effects, which are seen in the current state of the art specific immunotherapy routes, could be avoided. Therefore, in this study a penetration enhancing microemulsion was developed and its physicochemical properties were determined under several storage conditions. The influence of different preservatives on the microemulsion stability was observed. We examined epidermal penetration of Alexa Fluor-647 labelled bee-venom phospholipase A2 (Api m 1) using the Franz diffusion cell set up and confocal laser-scanning microscopy. First results of an in-vivo Api m 1-allergic mouse model indicated the protective efficacy of dermal AIT with our newly developed microemulsion. Summarily, the developed microemulsion is a suitable, stable drug delivery system for the topical administration of proteogenic allergens into the epidermis and is able to reach dendritic cells in the skin.
Collapse
Affiliation(s)
- C Kiselmann
- Institute of Bioprocess Engineering and Pharmaceutical Technology, Technische Hochschule Mittelhessen - University of Applied Sciences, Wiesenstraße 14, 35390 Giessen, Germany.
| | - D Dobler
- Institute of Bioprocess Engineering and Pharmaceutical Technology, Technische Hochschule Mittelhessen - University of Applied Sciences, Wiesenstraße 14, 35390 Giessen, Germany
| | - T Schmidts
- Institute of Bioprocess Engineering and Pharmaceutical Technology, Technische Hochschule Mittelhessen - University of Applied Sciences, Wiesenstraße 14, 35390 Giessen, Germany
| | - A C Eicher
- Institute of Bioprocess Engineering and Pharmaceutical Technology, Technische Hochschule Mittelhessen - University of Applied Sciences, Wiesenstraße 14, 35390 Giessen, Germany
| | - C Möbs
- Clinical & Experimental Allergology, Department of Dermatology and Allergology, Philipps University Marburg, Baldingerstraße, 35043 Marburg, Germany
| | - W Pfützner
- Clinical & Experimental Allergology, Department of Dermatology and Allergology, Philipps University Marburg, Baldingerstraße, 35043 Marburg, Germany
| | - F Runkel
- Institute of Bioprocess Engineering and Pharmaceutical Technology, Technische Hochschule Mittelhessen - University of Applied Sciences, Wiesenstraße 14, 35390 Giessen, Germany; Faculty of Biology and Chemistry, Justus Liebig University, Ludwigstraße 23, 35390 Giessen, Germany
| |
Collapse
|
10
|
Arzt L, Bokanovic D, Schrautzer C, Laipold K, Möbs C, Pfützner W, Herzog SA, Vollmann J, Reider N, Bohle B, Aberer W, Sturm GJ. Immunological differences between insect venom-allergic patients with and without immunotherapy and asymptomatically sensitized subjects. Allergy 2018; 73:1223-1231. [PMID: 29171032 DOI: 10.1111/all.13368] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/17/2017] [Indexed: 11/30/2022]
Abstract
BACKGROUND Currently available tests are unable to distinguish between asymptomatic sensitization and clinically relevant Hymenoptera venom allergy. A reliable serological marker to monitor venom immunotherapy (VIT) does also not exist. Our aim was to find reliable serological markers to predict tolerance to bee and vespid stings. METHODS We included 77 asymptomatically sensitized subjects, 85 allergic patients with acute systemic sting reactions, and 61 allergic patients currently treated with VIT. Levels of sIgE and sIgG4 to bee and vespid venom, rApi m 1, and rVes v 5 were measured immediately after allergic sting reactions or before sting challenges and 4 weeks later. All sting challenges were tolerated. The inhibitory activity was determined using BAT inhibition and ELIFAB assay. RESULTS Median sIgG4 levels were 96-fold higher in VIT patients (P < .001) while sIgE/sIgG4 ratios were consistently lower (P < .001). The ELIFAB assay was paralleled by low sIgE/sIgG4 ratios in VIT patients, showing markedly higher allergen-blocking capacity (P < .001). An almost complete inhibition of the basophil response was seen in all patients treated with vespid venom, but not in those treated with bee venom. Four weeks after the sting, sIgE and sIgG4 levels were increased in allergic and asymptomatically sensitized patients, but not in VIT patients. CONCLUSION Immunological responses after stings varied in bee and vespid venom-allergic patients. In patients under VIT, sIgE and sIgG4 remained completely stable after sting challenges. Monitoring VIT efficacy was only possible in vespid venom allergy, and the sIgG4 threshold for rVes v 5 had the highest sensitivity to confirm tolerance. The BAT inhibition test was the most reliable tool to confirm tolerance on an individual basis.
Collapse
Affiliation(s)
- L. Arzt
- Department of Dermatology and Venerology Medical University of Graz Graz Austria
| | - D. Bokanovic
- Department of Dermatology and Venerology Medical University of Graz Graz Austria
| | - C. Schrautzer
- Department of Dermatology and Venerology Medical University of Graz Graz Austria
| | - K. Laipold
- Department of Dermatology and Venerology Medical University of Graz Graz Austria
| | - C. Möbs
- Clinical & Experimental Allergology, Department of Dermatology and Allergology Philipps‐University of Marburg Marburg Germany
| | - W. Pfützner
- Clinical & Experimental Allergology, Department of Dermatology and Allergology Philipps‐University of Marburg Marburg Germany
| | - S. A. Herzog
- Institute for Medical Informatics, Statistics and Documentation Medical University of Graz Graz Austria
| | - J. Vollmann
- Institute of Zoology University of Graz Graz Austria
| | - N. Reider
- Department of Dermatology, Venerology and Allergology Medical University of Innsbruck Innsbruck Austria
| | - B. Bohle
- Division of Cellular Allergology Institute of Pathophysiology and Allergy Research Medical University of Vienna Vienna Austria
| | - W. Aberer
- Department of Dermatology and Venerology Medical University of Graz Graz Austria
| | - G. J. Sturm
- Department of Dermatology and Venerology Medical University of Graz Graz Austria
| |
Collapse
|
11
|
Vizzardelli C, Gindl M, Roos S, Möbs C, Nagl B, Zimmann F, Sexl V, Kenner L, Neunkirchner A, Zlabinger GJ, Pickl WF, Pfützner W, Bohle B. Blocking antibodies induced by allergen-specific immunotherapy ameliorate allergic airway disease in a human/mouse chimeric model. Allergy 2018; 73:851-861. [PMID: 29159964 DOI: 10.1111/all.13363] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/15/2017] [Indexed: 12/19/2022]
Abstract
BACKGROUND Allergen-specific immunotherapy (AIT) induces specific blocking antibodies (Ab), which are claimed to prevent IgE-mediated reactions to allergens. Additionally, AIT modulates cellular responses to allergens, for example, by desensitizing effector cells, inducing regulatory T and B lymphocytes and immune deviation. It is still enigmatic which of these mechanisms mediate(s) clinical tolerance. We sought to address the role of AIT-induced blocking Ab separately from cellular responses in a chimeric human/mouse model of respiratory allergy. METHODS Nonobese diabetic severe combined immunodeficient γc-/- (NSG) mice received intraperitoneally allergen-reactive PBMC from birch pollen-allergic patients together with birch pollen extract and human IL-4. Engraftment was assessed by flow cytometry. Airway hyperresponsiveness (AHR) and bronchial inflammation were analyzed after intranasal challenges with allergen or PBS. Sera collected from patients before and during AIT with birch pollen were added to the allergen prior to intranasal challenge. The IgE-blocking activity of post-AIT sera was assessed in vitro. RESULTS Human cells were detected in cell suspensions of murine lungs and spleens indicating successful humanization. Humanized mice displayed a more pronounced AHR and bronchial inflammation when challenged with allergen compared to negative controls. Post-AIT sera exerted IgE-blocking activity. In contrast to pre-AIT sera, the presence of heterologous and autologous post-AIT sera significantly reduced the allergic airway inflammation and matched their IgE-blocking activity determined in vitro. CONCLUSION Our data demonstrate that post-AIT sera with IgE-blocking activity ameliorate allergic airway inflammation in a human/mouse chimeric model of respiratory allergy independently of AIT-induced cellular changes.
Collapse
Affiliation(s)
- C. Vizzardelli
- Institute of Pathophysiology and Allergy Research; Medical University of Vienna; Vienna Austria
| | - M. Gindl
- Institute of Pathophysiology and Allergy Research; Medical University of Vienna; Vienna Austria
| | - S. Roos
- Unit of Laboratory Animal Pathology; University of Veterinary Medicine Vienna; Vienna Austria
| | - C. Möbs
- Department of Dermatology and Allergology; Philipps University Marburg; Marburg Germany
| | - B. Nagl
- Institute of Pathophysiology and Allergy Research; Medical University of Vienna; Vienna Austria
| | - F. Zimmann
- Institute of Pathophysiology and Allergy Research; Medical University of Vienna; Vienna Austria
| | - V. Sexl
- Institute of Pharmacology and Toxicology; University of Veterinary Medicine Vienna; Vienna Austria
| | - L. Kenner
- Unit of Laboratory Animal Pathology; University of Veterinary Medicine Vienna; Vienna Austria
- Department of Experimental and Laboratory Animal Pathology; Medical University of Vienna; Vienna Austria
- Ludwig Boltzmann Institute for Cancer Research (LBI-CR); Vienna Austria
| | - A. Neunkirchner
- Institute of Immunology; Medical University of Vienna; Vienna Austria
| | - G. J. Zlabinger
- Institute of Immunology; Medical University of Vienna; Vienna Austria
| | - W. F. Pickl
- Institute of Immunology; Medical University of Vienna; Vienna Austria
| | - W. Pfützner
- Department of Dermatology and Allergology; Philipps University Marburg; Marburg Germany
| | - B. Bohle
- Institute of Pathophysiology and Allergy Research; Medical University of Vienna; Vienna Austria
| |
Collapse
|
12
|
Rauber MM, Pickert J, Holiangu L, Möbs C, Pfützner W. Functional and phenotypic analysis of basophils allows determining distinct subtypes in patients with chronic urticaria. Allergy 2017; 72:1904-1911. [PMID: 28585360 DOI: 10.1111/all.13215] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/31/2017] [Indexed: 11/28/2022]
Abstract
BACKGROUND Chronic urticaria (CU) is a frequent skin disease characterized by relapsing appearance of pruritic hives. While clinical symptoms are due to the release of histamine by cutaneous mast cells, the underlying pathophysiology is still unknown. However, previous studies indicate that basophils might be of relevance. Besides, the occurrence of autoantibodies against IgE or its receptor, FcεRI, and the therapeutic efficacy of anti-IgE antibodies imply that IgE-mediated mechanisms also play an important role in CU. METHODS Reactivity of CU patients' peripheral blood basophils (n=60) to specific anti-FcεRI and IgE-independent fMLP stimulation was determined by basophil activation test in comparison with patients suffering from IgE-mediated allergic rhinitis (n=10) and healthy controls (n=10). In addition, immunoglobulin receptor (FcεRI, FcγRII) expression and surface bound antibodies (IgE, IgG) were quantified on basophils. Furthermore, the autoreactive capacity of CU sera was evaluated and urticaria-related symptoms were assessed by both UCT and CU-Q2 oL. RESULTS Stimulating CU patients' basophils via FcεRI, we identified three distinct immunologic phenotypes. One subgroup of patients' basophils reacted to FcεRI stimulation, whereas the others had anti-FcεRI nonreactive basophils. Among the latter, a subgroup with pronounced basopenia was identified. Of note, this group was characterized by augmented serum-induced basophil activation, increased levels of autoantibodies against thyroid peroxidase, and also exhibited the strongest disease impact on their quality of life. CONCLUSIONS Patients with CU can be categorized into three immunologic subgroups based on their basophil reactivity and frequency. These phenotypes are associated with different clinical characteristics, pointing to basophils as important players in CU pathophysiology.
Collapse
Affiliation(s)
- M. M. Rauber
- Clinical & Experimental Allergology; Department of Dermatology and Allergology; Philipps University Marburg; Marburg Germany
| | - J. Pickert
- Department of Dermatology and Allergology; Allergy Center Hessen; University Medical Center Gießen and Marburg; Marburg Germany
| | - L. Holiangu
- Department of Dermatology and Allergology; Allergy Center Hessen; University Medical Center Gießen and Marburg; Marburg Germany
| | - C. Möbs
- Clinical & Experimental Allergology; Department of Dermatology and Allergology; Philipps University Marburg; Marburg Germany
| | - W. Pfützner
- Clinical & Experimental Allergology; Department of Dermatology and Allergology; Philipps University Marburg; Marburg Germany
- Department of Dermatology and Allergology; Allergy Center Hessen; University Medical Center Gießen and Marburg; Marburg Germany
| |
Collapse
|
13
|
Groh N, von Loetzen CS, Subbarayal B, Möbs C, Vogel L, Hoffmann A, Fötisch K, Koutsouridou A, Randow S, Völker E, Seutter von Loetzen A, Rösch P, Vieths S, Pfützner W, Bohle B, Schiller D. IgE and allergen-specific immunotherapy-induced IgG 4 recognize similar epitopes of Bet v 1, the major allergen of birch pollen. Clin Exp Allergy 2016; 47:693-703. [PMID: 27770477 DOI: 10.1111/cea.12835] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2016] [Revised: 09/14/2016] [Accepted: 09/26/2016] [Indexed: 12/20/2022]
Abstract
BACKGROUND Allergen-specific immunotherapy (AIT) with birch pollen generates Bet v 1-specific immunoglobulin (Ig)G4 which blocks IgE-mediated hypersensitivity mechanisms. Whether IgG4 specific for Bet v 1a competes with IgE for identical epitopes or whether novel epitope specificities of IgG4 antibodies are developed is under debate. OBJECTIVE We sought to analyze the epitope specificities of IgE and IgG4 antibodies from sera of patients who received AIT. METHODS 15 sera of patients (13/15 received AIT) with Bet v 1a-specific IgE and IgG4 were analyzed. The structural arrangements of recombinant (r)Bet v 1a and rBet v 1a_11x , modified in five potential epitopes, were analyzed by circular dichroism and nuclear magnetic resonance spectroscopy. IgE binding to Bet v 1 was assessed by ELISA and mediator release assays. Competitive binding of monoclonal antibodies specific for Bet v 1a and serum IgE/IgG4 to rBet v 1a and serum antibody binding to a non-allergenic Bet v 1-type model protein presenting an individual epitope for IgE was analyzed in ELISA and western blot. RESULTS rBet v 1a_11x had a Bet v 1a - similar secondary and tertiary structure. Monomeric dispersion of rBet v 1a_11x was concentration and buffer-dependent. Up to 1500-fold increase in the EC50 for IgE-mediated mediator release induced by rBet v 1a_11x was determined. The reduction of IgE and IgG4 binding to rBet v 1a_11x was comparable in 67% (10/15) of sera. Bet v 1a-specific monoclonal antibodies inhibited binding of serum IgE and IgG4 to 66.1% and 64.9%, respectively. Serum IgE and IgG4 bound specifically to an individual epitope presented by our model protein in 33% (5/15) of sera. CONCLUSION AND CLINICAL RELEVANCE Patients receiving AIT develop Bet v 1a-specific IgG4 which competes with IgE for partly identical or largely overlapping epitopes. The similarities of epitopes for IgE and IgG4 might stimulate the development of epitope-specific diagnostics and therapeutics.
Collapse
Affiliation(s)
- N Groh
- Division of Allergology, Paul-Ehrlich-Institut, Langen, Germany
| | - C S von Loetzen
- Department of Biopolymers, University of Bayreuth, Bayreuth, Germany
| | - B Subbarayal
- Department of Pathophysiology and Allergy Research and Christian Doppler Laboratory for Immunomodulation, Medical University of Vienna, Vienna, Austria
| | - C Möbs
- Department of Dermatology and Allergology, Philipps University Marburg, Marburg, Germany
| | - L Vogel
- Division of Allergology, Paul-Ehrlich-Institut, Langen, Germany
| | - A Hoffmann
- Division of Allergology, Paul-Ehrlich-Institut, Langen, Germany
| | - K Fötisch
- Division of Allergology, Paul-Ehrlich-Institut, Langen, Germany
| | - A Koutsouridou
- Division of Allergology, Paul-Ehrlich-Institut, Langen, Germany
| | - S Randow
- Division of Allergology, Paul-Ehrlich-Institut, Langen, Germany
| | - E Völker
- Division of Allergology, Paul-Ehrlich-Institut, Langen, Germany
| | | | - P Rösch
- Department of Biopolymers, University of Bayreuth, Bayreuth, Germany
| | - S Vieths
- Division of Allergology, Paul-Ehrlich-Institut, Langen, Germany
| | - W Pfützner
- Department of Dermatology and Allergology, Philipps University Marburg, Marburg, Germany
| | - B Bohle
- Department of Pathophysiology and Allergy Research and Christian Doppler Laboratory for Immunomodulation, Medical University of Vienna, Vienna, Austria
| | - D Schiller
- Division of Allergology, Paul-Ehrlich-Institut, Langen, Germany
| |
Collapse
|
14
|
Baum C, Bieker K, Möbs C, Pfützner W. 415 Detection of interleukin-10-producing B cells in patients with birch pollen allergy and healthy controls. J Invest Dermatol 2016. [DOI: 10.1016/j.jid.2016.06.435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
15
|
Möbs C, Müller J, Rudzio A, Pickert J, Blank S, Jakob T, Spillner E, Pfützner W. Decline of Ves v 5-specific blocking capacity in wasp venom-allergic patients after stopping allergen immunotherapy. Allergy 2015; 70:715-9. [PMID: 25753563 DOI: 10.1111/all.12606] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/04/2015] [Indexed: 11/26/2022]
Abstract
While allergen-specific immunotherapy (AIT) is very efficient in hymenoptera venom (HV)-allergic patients, long-term outcome after finishing AIT is not well investigated, especially regarding mechanisms that are suggested to contribute to allergen-specific tolerance. Here, we analyse the Ves v 5-inhibitory activity of sera from wasp venom-allergic patients using the novel cell-free enzyme-linked immunosorbent facilitated antigen binding (ELIFAB) assay. Compared to pre-AIT, sera from patients undergoing AIT displayed an increased ability to inhibit Ves v 5 binding by IgE antibodies. In contrast, this inhibitory activity was reduced in patients having finished AIT 5-12 years ago. Allergen-blocking capacity correlated with serum concentrations of Ves v 5-specific IgG4 which rose during AIT but almost reached pretreatment levels in patients who had stopped AIT more than 5 years ago. These data raise questions about how long allergen tolerance is maintained in AIT-treated HV-allergic patients and suggest that the ELIFAB assay might be an easy-to-use tool assessing long-term tolerance in patients treated with HV-AIT.
Collapse
Affiliation(s)
- C. Möbs
- Clinical & Experimental Allergology; Department of Dermatology and Allergology; Philipps University Marburg; Marburg Germany
| | - J. Müller
- Clinical & Experimental Allergology; Department of Dermatology and Allergology; Philipps University Marburg; Marburg Germany
| | - A. Rudzio
- Clinical & Experimental Allergology; Department of Dermatology and Allergology; Philipps University Marburg; Marburg Germany
| | - J. Pickert
- Clinical & Experimental Allergology; Department of Dermatology and Allergology; Philipps University Marburg; Marburg Germany
| | - S. Blank
- Center of Allergy and Environment (ZAUM); Helmholtz Center Munich; Technical University Munich; Munich Germany
| | - T. Jakob
- Allergy Research Group; Department of Dermatology; Medical Center; University of Freiburg; Freiburg Germany
| | - E. Spillner
- Immunological Engineering; Department of Engineering; Aarhus University; Aarhus Denmark
| | - W. Pfützner
- Clinical & Experimental Allergology; Department of Dermatology and Allergology; Philipps University Marburg; Marburg Germany
| |
Collapse
|
16
|
Möbs C, Cornelissen C, Rauber M, Hertl M, Baron JM, Pfützner W. Modulation der IL-31 Serumkonzentration durch spezifische Immuntherapie bei Patienten mit IgE-vermitteltem Asthma bronchiale und allergischer Rhinitis. Pneumologie 2014. [DOI: 10.1055/s-0033-1363103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
17
|
Subbarayal B, Schiller D, Möbs C, de Jong NW, Ebner C, Reider N, Bartel D, Lidholm J, Pfützner W, Gerth van Wijk R, Vieths S, Bohle B. Kinetics, cross-reactivity, and specificity of Bet v 1-specific IgG4 antibodies induced by immunotherapy with birch pollen. Allergy 2013; 68:1377-86. [PMID: 24053565 DOI: 10.1111/all.12236] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/07/2013] [Indexed: 01/07/2023]
Abstract
BACKGROUND IgE antibodies specific for the major birch pollen allergen frequently cross-react with Bet v 1 homologous food proteins, for example Cor a 1 in hazelnut and Mal d 1 in apple. Specific immunotherapy with birch pollen (BP-SIT) induces IgG4 antibodies that inhibit IgE binding to Bet v 1. However, information on cross-reactivity of BP-SIT-induced Bet v 1-specific IgG4 antibodies with food allergens is limited. In this study, we investigated the kinetics of production, cross-reactivity, and IgE-blocking activity of Bet v 1-specific IgG4 antibodies emerging during conventional BP-SIT and whether IgG4-epitopes overlapped with IgE epitopes. METHODS IgE and IgG4 levels specific for Bet v 1, Mal d 1, and Cor a 1 were determined in 42 birch pollen-allergic patients before and during BP-SIT. Inhibition of IgE binding was studied by IgE-facilitated antigen-binding assays and basophil activation tests. Furthermore, inhibition of IgE-mediated activation of food allergen-reactive Bet v 1-specific T-cell lines was assessed. Competitive immunoscreening of phage-displayed peptides was applied to select mimotopes recognized by IgE and IgG4 antibodies, respectively. The resulting mimotopes were mapped on the surface of the 3D structure of the allergens using a computer-based algorithm. RESULTS BP-SIT significantly increased Bet v 1- and food allergen-reactive IgG4 antibodies. In parallel, allergen-specific IgE levels decreased significantly. Sera containing food allergen-reactive IgG4 antibodies inhibited IgE binding, basophil activation, and IgE-mediated food allergen-induced T-cell proliferation. Predicted IgE and IgG4 epitopes on all allergens showed high overlap. CONCLUSION Our results indicate that BP-SIT may induce Bet v 1-specific IgG4 antibodies that cross-react with related food allergens and inhibit IgE binding by epitope competition.
Collapse
Affiliation(s)
- B. Subbarayal
- Department of Pathophysiology and Allergy Research and Christian Doppler Laboratory for Immunomodulation; Medical University of Vienna; Vienna Austria
| | - D. Schiller
- Division of Allergology; Paul-Ehrlich-Institut; Langen Germany
| | - C. Möbs
- Department of Dermatology and Allergology; Philipps University Marburg; Marburg Germany
| | - N. W. de Jong
- Section of Allergology; Department of Internal Medicine; Erasmus Medical Center; Rotterdam the Netherlands
| | - C. Ebner
- Allergy Clinic Reumannplatz; Vienna Austria
| | - N. Reider
- Department of Dermatology; University Clinic Innsbruck; Innsbruck Austria
| | - D. Bartel
- Division of Allergology; Paul-Ehrlich-Institut; Langen Germany
| | - J. Lidholm
- Thermo Fisher Scientific; Uppsala Sweden
| | - W. Pfützner
- Department of Dermatology and Allergology; Philipps University Marburg; Marburg Germany
| | - R. Gerth van Wijk
- Section of Allergology; Department of Internal Medicine; Erasmus Medical Center; Rotterdam the Netherlands
| | - S. Vieths
- Division of Allergology; Paul-Ehrlich-Institut; Langen Germany
| | - B. Bohle
- Department of Pathophysiology and Allergy Research and Christian Doppler Laboratory for Immunomodulation; Medical University of Vienna; Vienna Austria
| |
Collapse
|
18
|
Groh N, Subbarayal B, Vogel L, Möbs C, de Jong NW, Pfützner W, van Wijk RG, Lidholm J, Meisel L, Randow S, Holzhauser T, Bohle B, Vieths S, Schiller D. Immunoglobulin E and G4 epitopes of the major allergen of birch pollen Bet v 1 share residues critical for antibody binding. Clin Transl Allergy 2013. [PMCID: PMC3723447 DOI: 10.1186/2045-7022-3-s3-o15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
19
|
Behzad M, Möbs C, Kneisel A, Möller M, Hoyer J, Hertl M, Eming R. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris. Br J Dermatol 2012; 166:844-52. [DOI: 10.1111/j.1365-2133.2011.10732.x] [Citation(s) in RCA: 67] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
|